Please login to the form below

Not currently logged in

TNF blockers to carry cancer warning

Anti-inflammatory drugs known as TNF blockers are to carry stronger warnings about the increased risk of sometimes fatal cancer

Anti-inflammatory drugs known as tumour necrosis factor (TNF) blockers are to carry stronger warnings about the increased risk of sometimes fatal cancer in children and adolescents, the Food and Drug Administration (FDA) has said.

The decision concludes an investigation that began last year, in which the regulator examined a possible link between anti-TNF therapies and cancer. Analysis of reports of cancer in patients receiving the drugs showed that the increased risk occurred "after 30 months of treatment on average".

Around half of the cancers were lymphomas and some of the reported cancers were fatal, the FDA noted.

Revised prescribing information and updated boxed warnings will affect Johnson & Johnson's and Schering-Plough's Remicade (infliximab) and Simponi (golimumab); Amgen and Wyeth's Enbrel (etanercept); Abbott's Humira (adalimumab) and UCB's Cimzia (certolizumab).

The FDA has said it is working with the manufacturers to better determine the risk of cancer in children and adolescents who use the drugs, which are used to treat rheumatoid arthritis and the bowel ailment Crohn's disease, along with other inflammatory diseases.

5th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...